HFS
CBAY

Hantz Financial Services’s Cymabay Therapeutics CBAY Stock Holding History

Hantz Financial Services’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-75
Closed – – 875
2021
Q2 		$0 Hold
75
– – ﹤0.01% 851
2021
Q1 		$0 Buy
+75
New +$404 ﹤0.01% 739

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hantz Financial Services's CBAY Position: Q3 2021 in Review

Hantz Financial Services sold out of Cymabay Therapeutics (CBAY) in Q3 2021, closing a stake of 75 shares.

Hantz Financial Services first reported a position in CBAY in Q1 2021 and held it in 2 quarters. The position peaked at $0 in Q2 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q3 2021.

  • Hantz Financial Services reported no remaining Cymabay Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hantz Financial Services sold 75 Cymabay Therapeutics shares in Q3 2021.
  • Hantz Financial Services first reported a position in Cymabay Therapeutics in Q1 2021 and held it in 2 quarters.
  • Hantz Financial Services's Cymabay Therapeutics position peaked at $0 in Q2 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2021.

Based on Hantz Financial Services's 13F filing for Q3 2021, filed 1 Sep 2022.